Suppr超能文献

血管紧张素 -(1 - 12)是心脏中血管紧张素肽产生的替代底物。

Angiotensin-(1-12) is an alternate substrate for angiotensin peptide production in the heart.

作者信息

Trask Aaron J, Jessup Jewell A, Chappell Mark C, Ferrario Carlos M

机构信息

Hypertension and Vascular Research Center, Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA.

出版信息

Am J Physiol Heart Circ Physiol. 2008 May;294(5):H2242-7. doi: 10.1152/ajpheart.00175.2008. Epub 2008 Mar 21.

Abstract

Identification of angiotensin-(1-12) as an intermediate precursor derived directly from angiotensinogen led us to explore whether the heart has the capacity to process angiotensin-(1-12) into biologically active angiotensin peptides. The generation of angiotensin I, angiotensin II, and angiotensin-(1-7) from exogenous angiotensin-(1-12) was evaluated in the effluent of isolated perfused hearts mounted on a Langendorff apparatus in three normotensive and two hypertensive strains: Sprague-Dawley, Lewis, congenic mRen2.Lewis, Wistar-Kyoto, and spontaneously hypertensive rats. Hearts were perfused with Krebs solution for 60 min before and after the addition of angiotensin-(1-12) (10 nmol/l). Angiotensin-(1-12) caused the rapid appearance of both angiotensin I and angiotensin II in the perfusate that peaked between 30 and 60 min of recirculation. Production of angiotensin-(1-7) from exogenous angiotensin-(1-12) rose steadily over the course of the 60-min experiment. These data directly demonstrate that angiotensin-(1-12) is a substrate for the formation of angiotensin peptides in cardiac tissue. This finding further suggests that this angiotensinogen-derived product is a previously unrecognized important precursor peptide to the renin-angiotensin system cascade.

摘要

将血管紧张素 -(1 - 12)鉴定为直接源自血管紧张素原的中间前体,促使我们探究心脏是否有能力将血管紧张素 -(1 - 12)加工成具有生物活性的血管紧张素肽。在安装于Langendorff装置上的离体灌注心脏的流出液中,评估了三种正常血压和两种高血压品系(Sprague - Dawley、Lewis、同源mRen2.Lewis、Wistar - Kyoto和自发性高血压大鼠)中外源性血管紧张素 -(1 - 12)生成血管紧张素I、血管紧张素II和血管紧张素 -(1 - 7)的情况。在添加血管紧张素 -(1 - 12)(10 nmol/l)之前和之后,心脏用Krebs溶液灌注60分钟。血管紧张素 -(1 - 12)导致灌注液中血管紧张素I和血管紧张素II迅速出现,在再循环30至60分钟时达到峰值。在60分钟的实验过程中,外源性血管紧张素 -(1 - 12)生成血管紧张素 -(1 - 7)的量稳步上升。这些数据直接表明血管紧张素 -(1 - 12)是心脏组织中血管紧张素肽形成的底物。这一发现进一步表明,这种源自血管紧张素原的产物是肾素 - 血管紧张素系统级联反应中一种先前未被认识的重要前体肽。

相似文献

1
Angiotensin-(1-12) is an alternate substrate for angiotensin peptide production in the heart.
Am J Physiol Heart Circ Physiol. 2008 May;294(5):H2242-7. doi: 10.1152/ajpheart.00175.2008. Epub 2008 Mar 21.
2
Sex differences in circulating and renal angiotensins of hypertensive mRen(2). Lewis but not normotensive Lewis rats.
Am J Physiol Heart Circ Physiol. 2008 Jul;295(1):H10-20. doi: 10.1152/ajpheart.01277.2007. Epub 2008 May 2.
3
Differential regulation of angiotensin-(1-12) in plasma and cardiac tissue in response to bilateral nephrectomy.
Am J Physiol Heart Circ Physiol. 2009 Apr;296(4):H1184-92. doi: 10.1152/ajpheart.01114.2008. Epub 2009 Feb 13.
4
Primary role of angiotensin-converting enzyme-2 in cardiac production of angiotensin-(1-7) in transgenic Ren-2 hypertensive rats.
Am J Physiol Heart Circ Physiol. 2007 Jun;292(6):H3019-24. doi: 10.1152/ajpheart.01198.2006. Epub 2007 Feb 16.
7
Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats.
Am J Physiol Heart Circ Physiol. 2006 Nov;291(5):H2166-72. doi: 10.1152/ajpheart.00061.2006. Epub 2006 Jun 9.
8
Plasma and tissue concentrations of proangiotensin-12 in rats treated with inhibitors of the renin-angiotensin system.
Hypertens Res. 2012 Feb;35(2):234-8. doi: 10.1038/hr.2011.165. Epub 2011 Oct 13.
9
Divergent pathways for the angiotensin-(1-12) metabolism in the rat circulation and kidney.
Peptides. 2012 Jun;35(2):190-5. doi: 10.1016/j.peptides.2012.03.025. Epub 2012 Apr 3.
10
Primacy of angiotensin converting enzyme in angiotensin-(1-12) metabolism.
Am J Physiol Heart Circ Physiol. 2013 Sep 1;305(5):H644-50. doi: 10.1152/ajpheart.00210.2013. Epub 2013 Jun 28.

引用本文的文献

1
Coronary cytoskeletal modulation of coronary blood flow in the presence and absence of type 2 diabetes: the role of cofilin.
Front Physiol. 2025 Mar 18;16:1561867. doi: 10.3389/fphys.2025.1561867. eCollection 2025.
2
Is chymase 1 a therapeutic target in cardiovascular disease?
Expert Opin Ther Targets. 2023 Jul-Dec;27(8):645-656. doi: 10.1080/14728222.2023.2247561. Epub 2023 Aug 21.
3
The renin-angiotensin system biomolecular cascade: a 2022 update of newer insights and concepts.
Kidney Int Suppl (2011). 2022 Apr;12(1):36-47. doi: 10.1016/j.kisu.2021.11.002. Epub 2022 Mar 18.
4
Immunoneutralization of human angiotensin-(1-12) with a monoclonal antibody in a humanized model of hypertension.
Peptides. 2022 Mar;149:170714. doi: 10.1016/j.peptides.2021.170714. Epub 2021 Dec 18.
5
Angiotensin (1-12) in Humans With Normal Blood Pressure and Primary Hypertension.
Hypertension. 2021 Mar 3;77(3):882-890. doi: 10.1161/HYPERTENSIONAHA.120.16514. Epub 2021 Jan 19.
6
The Angiotensin-(1-12)/Chymase axis as an alternate component of the tissue renin angiotensin system.
Mol Cell Endocrinol. 2021 Jun 1;529:111119. doi: 10.1016/j.mce.2020.111119. Epub 2020 Dec 10.
7
Differential Expression of the Angiotensin-(1-12)/Chymase Axis in Human Atrial Tissue.
J Surg Res. 2020 Sep;253:173-184. doi: 10.1016/j.jss.2020.03.051. Epub 2020 Apr 30.
8
Activation of the Human Angiotensin-(1-12)-Chymase Pathway in Rats With Human Angiotensinogen Gene Transcripts.
Front Cardiovasc Med. 2019 Nov 15;6:163. doi: 10.3389/fcvm.2019.00163. eCollection 2019.
9
Angiotensin-(1-12)/chymase axis modulates cardiomyocyte L-type calcium currents in rats expressing human angiotensinogen.
Int J Cardiol. 2019 Dec 15;297:104-110. doi: 10.1016/j.ijcard.2019.09.052. Epub 2019 Oct 8.
10
Nicotine and the renin-angiotensin system.
Am J Physiol Regul Integr Comp Physiol. 2018 Nov 1;315(5):R895-R906. doi: 10.1152/ajpregu.00099.2018. Epub 2018 Aug 8.

本文引用的文献

1
Localization of the novel angiotensin peptide, angiotensin-(1-12), in heart and kidney of hypertensive and normotensive rats.
Am J Physiol Heart Circ Physiol. 2008 Jun;294(6):H2614-8. doi: 10.1152/ajpheart.91521.2007. Epub 2008 Apr 11.
4
Primary role of angiotensin-converting enzyme-2 in cardiac production of angiotensin-(1-7) in transgenic Ren-2 hypertensive rats.
Am J Physiol Heart Circ Physiol. 2007 Jun;292(6):H3019-24. doi: 10.1152/ajpheart.01198.2006. Epub 2007 Feb 16.
5
Isolation and identification of proangiotensin-12, a possible component of the renin-angiotensin system.
Biochem Biophys Res Commun. 2006 Dec 1;350(4):1026-31. doi: 10.1016/j.bbrc.2006.09.146. Epub 2006 Oct 5.
6
Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors.
Kidney Int. 2005 Nov;68(5):2189-96. doi: 10.1111/j.1523-1755.2005.00675.x.
7
Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2.
Circulation. 2005 May 24;111(20):2605-10. doi: 10.1161/CIRCULATIONAHA.104.510461. Epub 2005 May 16.
8
Angiotensin-(1-7) formation in the intact human heart: in vivo dependence on angiotensin II as substrate.
Circulation. 2003 Oct 7;108(14):1679-81. doi: 10.1161/01.CIR.0000094733.61689.D4. Epub 2003 Sep 22.
9
The synthesis of a tetradecapeptide renin substrate.
J Exp Med. 1958 Sep 1;108(3):283-97. doi: 10.1084/jem.108.3.283.
10
Estrogen or the AT1 antagonist olmesartan reverses the development of profound hypertension in the congenic mRen2. Lewis rat.
Hypertension. 2003 Oct;42(4):781-6. doi: 10.1161/01.HYP.0000085210.66399.A3. Epub 2003 Jul 21.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验